| βIII-Tubulin: biomarker of taxane resistance or drug target? R Karki, M Mariani, M Andreoli, S He, G Scambia, S Shahabi, C Ferlini Expert opinion on therapeutic targets 17 (4), 461-472, 2013 | 108 | 2013 |
| Class III β-tubulin in normal and cancer tissues M Mariani, R Karki, M Spennato, D Pandya, S He, M Andreoli, P Fiedler, ... Gene 563 (2), 109-114, 2015 | 96 | 2015 |
| HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer M Mariani, M McHugh, M Petrillo, S Sieber, S He, M Andreoli, Z Wu, ... Oncotarget 5 (13), 4855, 2014 | 42 | 2014 |
| Detection boundary and higher criticism approach for rare and weak genetic effects Z Wu, Y Sun, S He, J Cho, H Zhao, J Jin | 40 | 2014 |
| Epstein-Barr virus microRNA expression increases aggressiveness of solid malignancies D Pandya, M Mariani, S He, M Andreoli, M Spennato, C Dowell-Martino, ... PLoS One 10 (9), e0136058, 2015 | 32 | 2015 |
| Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer M De Donato, M Fanelli, M Mariani, G Raspaglio, D Pandya, S He, ... American journal of cancer research 5 (6), 1862, 2015 | 32 | 2015 |
| Herpes virus microRNA expression and significance in serous ovarian cancer D Pandya, M Mariani, M McHugh, M Andreoli, S Sieber, S He, ... PloS one 9 (12), e114750, 2014 | 27 | 2014 |
| Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancer M Mariani, S He, M McHugh, M Andreoli, D Pandya, S Sieber, Z Wu, ... PLoS One 9 (7), e101065, 2014 | 20 | 2014 |
| Free testosterone drives cancer aggressiveness: evidence from US population studies S Shahabi, S He, M Kopf, M Mariani, J Petrini, G Scambia, C Ferlini PLoS One 8 (4), e61955, 2013 | 15 | 2013 |
| Gene-based Higher Criticism methods for large-scale exonic single-nucleotide polymorphism data S He, Z Wu BMC proceedings 5, 1-6, 2011 | 11 | 2011 |
| Association between loop diuretic dose administered in first 24 hours of heart failure admissions and length of hospital stay AR Elashery, K Aykent, H Kurdi, M Ibrahim, S He, JR Petrini, HM Kramer Journal of Community Hospital Internal Medicine Perspectives 8 (4), 195-199, 2018 | 1 | 2018 |
| NSAIDs Use after Breast Cancer Diagnosis Improves Relapse-Free and Overall Survival: Retrospective Pilot Study N Sostin, S He, O Sostin, M Troxell American Journal of Clinical Pathology 146 (suppl_1), 315, 2016 | 1 | 2016 |
| Alpha-1 Antitrypsin Patients' Perceptions Regarding Lung Cancer Risk And Screening S Kariyawasam, A Butler, S He, CB Strange, D Kahn C30. LUNG CANCER SCREENING: WHO, WHY, WHERE, AND HOW MUCH, A5192-A5192, 2017 | | 2017 |
| MiR-BART9 is a prognostic biomarker associated with PD-1 expression in colon cancer patients M Mariani, D Pandya, M Andreoli, S He, M Spennato, C Ferlini Cancer Research 76 (14_Supplement), 3127-3127, 2016 | | 2016 |
| Ovarian Cancer Markers of Response to Neoadjuvant Chemotherapy MP McHugh, S Sieber, S He, M Andreoli, Z Wu, P Fiedler, G Scambia, ... | | 2014 |
